Effect of boron compounds on the biological effectiveness of proton therapy.
alpha particles
proton-boron capture therapy
proton-boron nuclear reaction
relative biological effectiveness
sensitization enhancement ratio
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
23
05
2022
received:
28
01
2022
accepted:
17
06
2022
pubmed:
28
6
2022
medline:
15
9
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
We assessed whether adding sodium borocaptate (BSH) or 4-borono-l-phenylalanine (BPA) to cells irradiated with proton beams influenced the biological effectiveness of those beams against prostate cancer cells to investigate if the alpha particles generated through proton-boron nuclear reactions would be sufficient to enhance the biological effectiveness of the proton beams. We measured clonogenic survival in DU145 cells treated with 80.4-ppm BSH or 86.9-ppm BPA, or their respective vehicles, after irradiation with 6-MV X-rays, 1.2-keV/μm (low linear energy transfer [LET]) protons, or 9.9-keV/μm (high-LET) protons. We also measured γH2AX and 53BP1 foci in treated cells at 1 and 24 h after irradiation with the same conditions. We found that BSH radiosensitized DU145 cells across all radiation types. However, no difference was found in relative radiosensitization, characterized by the sensitization enhancement ratio or the relative biological effectiveness, for vehicle- versus BSH-treated cells. No differences were found in numbers of γH2AX or 53BP1 foci or γH2AX/53BP1 colocalized foci for vehicle- versus BSH-treated cells across radiation types. BPA did not radiosensitize DU145 cells nor induced any significant differences when comparing vehicle- versus BPA-treated cells for clonogenic cell survival or γH2AX and 53BP1 foci or γH2AX/53BP1 colocalized foci. Treatment with
Substances chimiques
Boron Compounds
0
Protons
0
Phenylalanine
47E5O17Y3R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6098-6109Subventions
Organisme : TAE Life Sciences
Organisme : the Department of Radiation Physics (Department chair funds from Dr. Mary K. Martel), The University of Texas MD Anderson Cancer Center
Organisme : the Division of Radiation Oncology Strategic Initiatives, The University of Texas MD Anderson Cancer Center
Organisme : the NCI/NIH Cancer Center Support (Core) Grant P30 CA011672 to The University of Texas MD Anderson Cancer Center
Informations de copyright
© 2022 American Association of Physicists in Medicine.
Références
Yoon D-K, Jung J-Y, Suh TS. Application of proton boron fusion reaction to radiation therapy: a Monte Carlo simulation study. Appl Phys Lett. 2014;105(22):223507.
Jung J-Y, Yoon D-K, Barraclough B, Lee HC, Suh TS, Lu B. Comparison between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT): a Monte Carlo study. Oncotarget. 2017;8(24):39774-39781.
Kim M-S, Law MW-M, Djeng S-K, et al. Synergy effect of alpha particles by using natural boron in proton therapy: computational verification. AIP Adv. 2019;9(11):115017.
Bláha P, Feoli C, Agosteo S, et al. The proton-boron reaction increases the radiobiological effectiveness of clinical low- and high-energy proton beams: novel experimental evidence and perspectives. Front Oncol. 2021;11(2122):682647.
Cirrone GAP, Manti L, Margarone D, et al. First experimental proof of proton boron capture therapy (PBCT) to enhance proton therapy effectiveness. Sci Rep. 2018;8(1):1141.
Ahmadi Ganjeh Z, Eslami-Kalantari M. Investigation of proton-boron capture therapy vs. proton therapy. Nucl Instrum Methods Phys Res A. 2020;977:164340.
Mazzone A, Finocchiaro P, Colonna N. On the (un)effectiveness of proton boron capture in proton therapy. Eur Phys J Plus. 2019;134(7):361.
Cirrone GAP, Petringa G, Attili A, et al. Study of the discrepancy between analytical calculations and the observed biological effectiveness in proton boron capture therapy (PBCT). Radiat Appl. 2018;3:147-151.
Yoon D-K, Naganawa N, Kimura M, et al. Application of proton boron fusion to proton therapy: experimental verification to detect the alpha particles. Appl Phys Lett. 2019;115(22):223701.
Tabbakh F, Hosmane NS. Enhancement of radiation effectiveness in proton therapy: comparison between fusion and fission methods and further approaches. Sci Rep. 2020;10(1):5466.
Khaledi N, Wang X, Hosseinabadi RB, Samiei F. Is the proton-boron fusion therapy effective?. J Radiother Pract. 2021;20(2):153-157. [published online ahead of print 2020/03/16].
Chiniforoush TA, Hadadi A, Kasesaz Y, Sardjono Y. Evaluation of effectiveness of equivalent dose during proton boron fusion therapy (PBFT) for brain cancer: a Monte Carlo study. Appl Radiat Isot. 2021;170:109596.
Meyer HJ, Titt U, Mohan R. Monte Carlo study of the mechanism of proton-boron fusion therapy. Med Phys. 2022;49(1):579-582.
Cadova E, Kriz O. Stability of sodium mercaptododecaborate [BSH, Na2B12H11SH] in water solution. (KURRI-KR-54). Kanda, Keiji (Ed.). Japan, in Proceedings of the ninth international symposium on neutron capture therapy for cancer. 2000.
van Rij CM, Sinjewel A, van Loenen AC, et al. Stability of 10B-l-boronophenylalanine-fructose injection. Am J Health Syst Pharm. 2005;62(24):2608-2610.
Berglund M, Wieser ME. Isotopic compositions of the elements 2009 (IUPAC Technical Report). Pure Appl Chem. 2011;83(2):397-410.
Bright S, Flint D, Chakraborty S, et al. Nonhomologous end joining is more important than proton linear energy transfer in dictating cell death. Int J Radiat Oncol Biol Phys. 2019;105:1119-1125.
Titt U, Sahoo N, Ding X, et al. Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions. Phys Med Biol. 2008;53:4455-4470.
Flint DB, Bright SJ, McFadden CH, et al. Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions. Med Phys. 2021;48:3243-3261.